EV Suseong Signs Supply Contract Worth 9.5 Billion KRW with China Daecheon Bio 향

[Asia Economy Reporter Jang Hyowon] EV Suseong announced on the 11th that it has signed a supply contract worth 9.5 billion KRW for 'Kovixil' with D35, a contracted company of Daqian Bio (Anhui Daqian Bioengineering Co., Ltd.) in China.

This amount corresponds to 35.51% of the 2021 sales revenue, and the contract period lasts until March 7.

Daqian Bio is an 'innovative biochemical in vitro diagnostic reagent company' authorized by the central government of China and the Anhui provincial authorities to manufacture and produce 127 types of in vitro diagnostic reagents.

Kovixil is a nasal spray product that has been verified to have over 99% neutralizing power against respiratory viruses including COVID-19 and influenza. It was developed with research and development support from the U.S. National Cancer Institute (NCI) and has been officially introduced through platforms such as Nature (Springer Nature) and the World Health Organization (WHO) global open access platform.

EV Suseong CEO Jang Taehoon explained, “Kovixil is produced by our affiliate Salbasion and supplied to Chinese distributors through EV Suseong. This supply contract corresponds to the first batch (initial order) of 10.8 million units signed with Daqian Bio on the 4th, and further sequential supplies are planned.”

Meanwhile, on December 27 last year, EV Suseong and Salbasion signed supply and distributor contracts for Korea, Japan, and China, and EV Suseong will change its company name to Suseong Salbasion.